FDA issues Letter to Clinical Laboratory Staff, Point-of-Care Staff, and Health Care Providers

If your email program has trouble displaying this email, view as a webpage. Potential for False Results with Roche cobas SARS-CoV-2 & Influenza Test for use on cobas Liat System FDA issues Letter to Clinical Laboratory Staff, Point-of-Care Staff, and Health Care Providers Today, the U.S. Food and Drug Administration (FDA) issued a Letter to Clinical Laboratory Staff, Point-of-Care Staff, and Health Care Providers to alert them that false positive results can occur with the Roche Molecular Systems, Inc. cobas SARS-CoV-2 and Influenza A/B Nucleic Acid Test for use on the cobas Liat System. Read More This Letter to Health Care Providers includes important information about the cobas SARS-CoV-2 and Influenza A/B Nucleic Acid Test for use on the cobas Liat System, including: Details on potential causes of false results with the cobas SARS-CoV-2 and Influenza A/B Nucleic Acid Test. Recommendations for cobas Liat System operators using the cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test. Actions the FDA has taken to address the issues. Instructions for reporting adverse events with a device to the FDA. Questions? If you have questions, email COVID19Dx@fda.hhs.gov.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA